Research programme: small molecule therapeutics - HUYA

Drug Profile

Research programme: small molecule therapeutics - HUYA

Latest Information Update: 18 Nov 2009

Price : $50

At a glance

  • Originator HUYA Bioscience International LLC; Organon
  • Developer HUYA Bioscience International
  • Class Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Unspecified

Most Recent Events

  • 20 Oct 2009 Preclinical development is ongoing in USA and China
  • 15 Dec 2008 HUYA Bioscience International and Organon announce a further drug development agreement
  • 19 Nov 2007 Organon has been acquired by Schering-Plough
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top